Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:DTIL NASDAQ:ELYM NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.27-0.4%$2.63$7.96▼$24.15$11.45M0.6315,685 shs75,076 shsDTILPrecision BioSciences$4.71-1.3%$4.67$3.61▼$11.09$56.22M1.52167,211 shs106,424 shsELYMEliem Therapeutics$1.72+5.5%$1.40$2.35▼$11.55$51.17M-0.39486,688 shs404,398 shsUNCYUnicycive Therapeutics$4.70+1.5%$5.28$2.75▼$11.00$58.53M1.88382,440 shs563,583 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-8.43%-13.64%-12.64%-35.59%-86.59%DTILPrecision BioSciences+1.71%+4.38%+7.19%+1.27%-46.76%ELYMEliem Therapeutics+1.24%-4.12%+14.79%+35.83%-72.88%UNCYUnicycive Therapeutics+4.99%+14.04%+0.22%-22.30%+46.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ADTILPrecision BioSciences4.1957 of 5 stars3.51.00.04.64.01.70.6ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics2.6308 of 5 stars3.72.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$47.00897.88% UpsideELYMEliem Therapeutics 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.33Buy$60.001,176.60% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, DTIL, UNCY, and ELYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ADTILPrecision BioSciences$68.70M0.81N/AN/A$2.89 per share1.63ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AUNCYUnicycive Therapeutics$680K87.36N/AN/A$0.72 per share6.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%N/ADTILPrecision BioSciences$7.17M-$8.810.00N/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AUNCYUnicycive Therapeutics-$36.73M-$5.100.00N/AN/AN/A-246.71%-116.96%N/ALatest ALVR, DTIL, UNCY, and ELYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025UNCYUnicycive Therapeutics-$0.70-$0.52+$0.18-$0.52N/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78DTILPrecision BioSciences0.665.185.18ELYMEliem TherapeuticsN/A60.4160.41UNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%DTILPrecision BioSciences37.99%ELYMEliem Therapeutics69.76%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%DTILPrecision BioSciences4.50%ELYMEliem Therapeutics4.70%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableDTILPrecision BioSciences20011.79 million11.26 millionNo DataELYMEliem Therapeutics929.75 million28.35 millionNot OptionableUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionableALVR, DTIL, UNCY, and ELYM HeadlinesRecent News About These CompaniesUnicycive Therapeutics reports Q2 EPS (52c), consensus (70c)August 14 at 12:07 AM | msn.comUnicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 14 at 4:14 PM | gurufocus.comUnicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 14 at 3:55 PM | globenewswire.comUnicycive Therapeutics requests Type A meeting with FDA to discuss CRLAugust 14 at 2:05 PM | msn.comUnicycive Therapeutics expects cash to fund operations into 2H of 2026August 14 at 2:05 PM | msn.comUnicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14 at 7:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYAugust 13 at 12:33 PM | globenewswire.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on WednesdayAugust 12 at 8:43 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYAugust 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYAugust 9, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLCAugust 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYAugust 6, 2025 | prnewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in JulyAugust 3, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 31, 2025 | prnewswire.comUnicycive Therapeutics Inc Ordinary Shares UNCY - MorningstarJuly 30, 2025 | morningstar.comMUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What HappenedJuly 30, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 27, 2025 | prnewswire.comUnicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of NephrologyJuly 24, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, DTIL, UNCY, and ELYM Company DescriptionsAlloVir NASDAQ:ALVR$2.27 -0.01 (-0.44%) As of 08/14/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Precision BioSciences NASDAQ:DTIL$4.71 -0.06 (-1.26%) Closing price 04:00 PM EasternExtended Trading$4.69 -0.02 (-0.42%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Eliem Therapeutics NASDAQ:ELYM$1.72 +0.09 (+5.52%) As of 08/14/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Unicycive Therapeutics NASDAQ:UNCY$4.70 +0.07 (+1.51%) Closing price 04:00 PM EasternExtended Trading$4.72 +0.02 (+0.43%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access